Edition:
United Kingdom

Steadymed Ltd (STDY.OQ)

STDY.OQ on NASDAQ Stock Exchange Global Market

4.50USD
17 Jul 2018
Change (% chg)

$-0.03 (-0.55%)
Prev Close
$4.53
Open
$4.50
Day's High
$4.53
Day's Low
$4.50
Volume
4,801
Avg. Vol
32,492
52-wk High
$6.80
52-wk Low
$2.65

Chart for

About

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing... (more)

Overall

Beta: --
Market Cap(Mil.): $84.98
Shares Outstanding(Mil.): 26.56
Dividend: --
Yield (%): --

Financials

  STDY.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -1.94 -- --
ROI: -128.53 2.29 14.61
ROE: -221.79 3.86 16.34

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

30 Apr 2018

BRIEF-United Therapeutics To Acquire SteadyMed For $4.46 Per Share In Cash

* STEADYMED - DEAL INCLUDES ADDITIONAL $2.63/SHARE IN CASH TO UNITED THERAPEUTICS UPON ACHIEVEMENT OF MILESTONE RELATED TO COMMERCIALIZATION OF TREVYENT

30 Apr 2018

BRIEF-Steadymed Reports Q4 Loss Per Share $0.22

* Q4 LOSS PER SHARE $0.22 Source text : http://bit.ly/2Gov1vO Further company coverage:

30 Mar 2018

Earnings vs. Estimates